Skip to main content
. 2021 Aug 31:aqab092. doi: 10.1093/ajcp/aqab092

Figure 3.

Figure 3

Cross-reactivity with samples derived from patients with a non-COVID-19 respiratory infection. Samples were obtained from 47 patients who tested concurrently positive for a non-SARS-CoV-2 respiratory infection and negative for SARS-CoV-2 by reverse transcription polymerase chain reaction (via the BioFire Respiratory 2.1 Panel). Among these patients, 2 tested positive for spike protein antibody (S-Ab). Given that they also tested positive via the qualitative nucleocapsid antibody (N-Ab) assay, these patients likely had a true SARS-CoV-2 infection that elicited antibody formation against both S and N antigens, as opposed to representing false positives of S-Ab and N-Ab assays due to cross-reactivity. aOne patient tested positive for rhinovirus/enterovirus and adenovirus, and therefore was counted toward the total for both categories. RSV, respiratory syncytial virus.